---
title: Assess confidence in thinking skills
nct_id: NCT07488377
status: RECRUITING
sponsor: Acibadem University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07488377"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07488377"
last_fetched: "2026-07-15T14:01:45.254Z"
source: "Parkinson's Pathways (curated)"
---
# Assess confidence in thinking skills

**Goal (in five words):** Assess confidence in thinking skills

**Official Title:** Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire in Individuals With Parkinson's Disease

**Trial ID:** [NCT07488377](https://clinicaltrials.gov/study/NCT07488377)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Acibadem University
- **Target Enrollment:** 100 participants
- **Start Date:** 2026-04-01
- **Completion Date:** 2027-01-01
- **Conditions:** Parkinson Disease
- **Interventions:** Cognitive Self-Efficacy Questionnaire (Turkish Version)
- **Intervention Types:** OTHER

## Summary For Families

Researchers are checking whether a Turkish version of the Cognitive Self-Efficacy Questionnaire gives accurate and consistent information about how confident people with Parkinson's feel about their thinking and memory. Adults who come to the Movement Disorders Outpatient Clinic will complete the Turkish questionnaire during study assessments, and the researchers will analyze the answers to judge how well the tool works. The study is looking for people aged 40 to 85 with early to mid-stage Parkinson's (stage 1 to 3), a score of 24 or higher on the mini-mental state exam (a brief thinking and memory test), who can communicate, complete assessments, and give written consent; people with major depression, psychosis, advanced dementia, or severe vision or hearing problems are not eligible.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(From the protocol)_:
- Questionnaires & surveys (Non-invasive)
  > "Cognitive Self-Efficacy Questionnaire (Turkish Version)"

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Clinical diagnosis of Parkinson's disease
* Hoehn and Yahr stage 1-3
* Age 40 to 85 years
* Mini-Mental State Examination (MMSE) score ≥24
* Able to communicate and complete study assessments
* Attending the Movement Disorders Outpatient Clinic, Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital
* Able and willing to provide written informed consent

Exclusion Criteria:

* Major depressive disorder or psychotic disorder
* Advanced dementia
* Severe visual impairment that may interfere with study assessments
* Severe hearing impairment that may interfere with study assessments
* Inability to cooperate with the physiotherapist
* Inability to complete the study assessments
```

## Locations (1)

- Acibadem University, Istanbul, Turkey, Turkey (Türkiye) _(41.0138, 28.9497)_
  - Nuray ALACA, (CONTACT), 05324251290, nuray.alaca@acibadem.edu.tr

## Central Contacts

- Nuray ALACA, (CONTACT), 05324251290, nuray.alaca@acibadem.edu.tr

---

*Canonical: https://parkinsonspathways.com/trial/NCT07488377*  
*HTML version: https://parkinsonspathways.com/trial/NCT07488377*  
*Source data: https://clinicaltrials.gov/study/NCT07488377*